Health State Utilities of Patients with Heart Failure: A Systematic Literature Review
- PDF / 989,676 Bytes
- 19 Pages / 595.276 x 790.866 pts Page_size
- 69 Downloads / 187 Views
SYSTEMATIC REVIEW
Health State Utilities of Patients with Heart Failure: A Systematic Literature Review Gian Luca Di Tanna1,7 · Michael Urbich2 · Heidi S. Wirtz3 · Barbara Potrata4 · Marieke Heisen4 · Craig Bennison5 · John Brazier6 · Gary Globe3 Accepted: 10 November 2020 © The Author(s) 2020
Abstract Background and Objectives New treatments and interventions are in development to address clinical needs in heart failure. To support decision making on reimbursement, cost-effectiveness analyses are frequently required. A systematic literature review was conducted to identify and summarize heart failure utility values for use in economic evaluations. Methods Databases were searched for articles published until June 2019 that reported health utility values for patients with heart failure. Publications were reviewed with specific attention to study design; reported values were categorized according to the health states, ‘chronic heart failure’, ‘hospitalized’, and ‘other acute heart failure’. Interquartile limits (25th percentile ‘Q1’, 75th percentile ‘Q3’) were calculated for health states and heart failure subgroups where there were sufficient data. Results The systematic literature review identified 161 publications based on data from 142 studies. Utility values for chronic heart failure were reported by 128 publications; 39 publications published values for hospitalized and three for other acute heart failure. There was substantial heterogeneity in the specifics of the study populations, methods of elicitation, and summary statistics, which is reflected in the wide range of utility values reported. EQ-5D was the most used instrument; the interquartile limit for mean EQ-5D values for chronic heart failure was 0.64–0.72. Conclusions There is a wealth of published utility values for heart failure to support economic evaluations. Data are heterogenous owing to specificities of the study population and methodology of utility value elicitation and analysis. Choice of value(s) to support economic models must be carefully justified to ensure a robust economic analysis.
Electronic supplementary material The online version of this article (https://doi.org/10.1007/s40273-020-00984-6) contains supplementary material, which is available to authorized users. * Gian Luca Di Tanna [email protected] 1
Statistics Division, The George Institute for Global Health, Faculty of Medicine, University of New South Wales, Sydney, NSW, Australia
2
Amgen (Europe) GmbH, Global Value & Access, Modeling Center of Excellence, Rotkreuz, Switzerland
3
Amgen Inc, Global Health Economics, Thousand Oaks, CA, USA
4
Pharmerit - an OPEN Health company, Rotterdam, The Netherlands
5
Pharmerit - an OPEN Health company, York, UK
6
Health Economics and Decision Science, University of Sheffield, Sheffield, UK
7
The George Institute for Global Health, Level 5, 1 King St, Newtown, NSW 2042, Australia
Key Points This systematic literature review identifies and summarizes utility values for heart failure (HF) to su
Data Loading...
